

Carenity PatientLive forays into oncology therapeutic area

18 June 2021 | News

Will offer 18 new PatientLive conditions related to cancer



Carenity, part of the technology-driven data science group EvidentIQ, announced that its PatientLive solution is broadening its offer by entering the oncology therapeutic area. The PatientLive Oncology platform grants access to real-time insights and reliable answers from cancer patients and caregivers with quick surveys.

Carenity's mission is to help improve medical knowledge and care for chronic patients, including patients with cancer, which is the driving force behind the opening of 18 new PatientLive conditions. These conditions, both in haematology and solid tumours, are bladder cancer, breast cancer, colorectal cancer, oesophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, lung cancer, mouth cancer, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, throat cancer, thyroid cancer, and tongue cancer.

PatientLive offered access to a worldwide online panel of 500,000 patients and caregivers in the following conditions: ankylosing spondylitis, arterial hypertension, asthma, bipolar disorder, COPD, Crohn's disease, depression, Diabetes (Types 1 and 2), epilepsy, fibromyalgia, lupus, multiple sclerosis, NASH, obesity, osteoarthritis, psoriasis, and rheumatoid arthritis.

Michael Chekroun, Chief Strategy and Transformation Officer at EvidentIQ group and Founder, Carenity, said, "PatientLive has always offered quick responses and has been valued for its simplicity and autonomy of use. We want now to make this available for pharma companies focusing on oncology and keep this virtuous circle of Data for Good going."